Serevent, Airexar spiromax(salmeterol xinafoate)
Advair, Airduo, Fluticasone / Salmeterol Xinafoate, Serevent, Spiromax, Wixela (salmeterol xinafoate) is a small molecule pharmaceutical. Salmeterol xinafoate was first approved as Serevent on 1994-02-04. It is used to treat asthma and bronchial spasm in the USA. It has been approved in Europe to treat asthma and chronic obstructive pulmonary disease.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Serevent (discontinued: Serevent)
CombinationsAdvair, Airduo, Fluticasone salmeterol xinafoate, Wixela (discontinued: Airduo)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluticasone propionate
+
Salmeterol xinafoate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ADVAIR DISKUS 100/50 | GSK | N-021077 RX | 2000-08-24 | 1 products, RLD, RS |
| ADVAIR DISKUS 250/50 | GSK | N-021077 RX | 2000-08-24 | 1 products, RLD, RS |
| ADVAIR DISKUS 500/50 | GSK | N-021077 RX | 2000-08-24 | 1 products, RLD, RS |
| ADVAIR HFA | GSK | N-021254 RX | 2006-06-08 | 3 products, RLD, RS |
| AIRDUO RESPICLICK | Teva | N-208799 RX | 2017-01-27 | 3 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| advair hfa | New Drug Application | 2025-08-08 |
| fluticasone propionate and salmeterol hfa | NDA authorized generic | 2024-05-29 |
| serevent | New Drug Application | 2022-10-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| asthma | EFO_0000270 | D001249 | J45 |
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| bronchial spasm | — | D001986 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FLUTICASONE PROPIONATE / SALMETEROL XINAFOATE, AIRDUO DIGIHALER, TEVA PHARM | |||
| 2025-01-09 | PED | ||
| 2024-07-09 | M-61 | ||
FLUTICASONE PROPIONATE / SALMETEROL XINAFOATE, AIRDUO RESPICLICK, TEVA PHARM | |||
| 2025-01-09 | PED | ||
| 2024-07-09 | M-61 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Fluticasone Propionate / Salmeterol Xinafoate, Airduo Digihaler, Teva Pharm | |||
| 11266796 | 2041-02-22 | DP | |
| 11173259 | 2040-07-06 | DP | |
| 11464923 | 2040-06-19 | DP | |
| 11439777 | 2040-05-24 | DP | |
| 11344685 | 2039-09-26 | DP | |
| 11000653 | 2038-12-18 | DP | |
| 11357935 | 2038-09-24 | DP | |
| 11351317 | 2038-02-10 | DP | |
| 10569034 | 2036-08-16 | DP | |
| 10918816 | 2035-12-14 | DP | |
| 9782550 | 2035-08-28 | DP | |
| 9782551 | 2035-08-28 | DP | |
| 9066957 | 2034-10-06 | DP | U-645 |
| 9415008 | 2034-10-06 | DP | U-645 |
| 8714149 | 2032-02-25 | DP | |
| 8978966 | 2032-01-13 | DP | |
| 10561808 | 2032-01-01 | DP | |
| 9216260 | 2031-06-28 | DP | |
| 9731087 | 2031-05-18 | DP | |
| 10022510 | 2031-05-18 | DP | |
| 10124131 | 2031-05-18 | DP | |
| 10195375 | 2031-02-14 | DP | |
| 8651103 | 2028-03-26 | DP | |
| 9463288 | 2025-05-19 | DP | |
| 10765820 | 2025-05-19 | DP | |
| 9616024 | 2024-09-01 | DP | |
| 9987229 | 2024-09-01 | DP | |
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AC: Selective beta-2-adrenoreceptor agonist inhalants
— R03AC12: Salmeterol
— R03AK: Adrenergics inhalants in combination with corticosteroids or other drugs, excl. anticholinergics
— R03AK06: Salmeterol and fluticasone
— R03AK12: Salmeterol and budesonide
HCPCS
No data
Clinical
Clinical Trials
419 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 23 | 23 | 59 | 65 | 37 | 206 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 11 | 24 | 57 | 52 | 30 | 172 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 3 | 13 | 46 | 32 | 18 | 112 |
| Obstructive lung diseases | D008173 | — | — | 4 | 15 | 35 | 35 | 21 | 109 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | 13 | 2 | 11 | 1 | 1 | 28 |
| Healthy volunteers/patients | — | — | — | 7 | — | — | 1 | 4 | 12 |
| Bronchitis | D001991 | — | J40 | — | — | 4 | 1 | 1 | 6 |
| Allergic rhinitis | D065631 | — | J30.9 | — | — | 1 | 3 | 1 | 5 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | — | 1 | 3 | 1 | 5 |
| Chronic disease | D002908 | — | — | — | — | 4 | 1 | — | 5 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract diseases | D012140 | — | — | — | — | 1 | — | 2 | 3 |
| Respiration disorders | D012120 | — | J00-J99 | — | — | 1 | — | 2 | 3 |
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | — | 1 | — | 1 | 2 |
| Bronchiolitis obliterans | D001989 | EFO_0007183 | J44.81 | — | — | 1 | — | — | 1 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | — | 1 | — | — | 1 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary eosinophilia | D011657 | EFO_0007257 | J82.81 | — | 1 | — | — | — | 1 |
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 14 | — | — | — | — | 14 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 2 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Respiratory signs and symptoms | D012818 | — | — | — | — | — | — | 1 | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 1 | 1 |
| Fibrosis | D005355 | — | — | — | — | — | — | 1 | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 1 | 1 |
| Nebulizers and vaporizers | D009330 | — | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Salmeterol xinafoate |
| INN | — |
| Description | 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol is a phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine. It is a member of phenols, an ether, a secondary alcohol, a primary alcohol and a secondary amino compound. It is functionally related to a phenylethanolamine. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (salicylic acid derivatives); bronchodilators (phenethylamine derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O |
Identifiers
| PDB | — |
| CAS-ID | 89365-50-4 |
| RxCUI | 36117 |
| ChEMBL ID | CHEMBL1082607 |
| ChEBI ID | — |
| PubChem CID | 5152 |
| DrugBank | DB00938 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,044 documents
View more details
Safety
Black-box Warning
Black-box warning for: Serevent
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
53,987 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use